Michael J Clayman, 66409 Scarlet Oak Dr, Fountain Inn, SC 29644

Michael Clayman Phones & Addresses

409 Scarlet Oak Dr, Fountain Inn, SC 29644

Pelzer, SC

1761 Dadeyville Rd, Austinburg, OH 44010

Ashtabula, OH

Gray Court, SC

Geneva, OH

Laurens, SC

Greenville, SC

Get Report

Control this profile

Mentions for Michael J Clayman

Career records & work history

License Records

Michael Douglas Clayman

Licenses:

License #: MT008083T - Expired
Category: Medicine
Type: Graduate Medical Trainee

Michael Clayman videos

Youtube

Michael Clayman Claymation

Duration:

4m 9s

Description:

not really michael clayton!!!

Acid! Interview (Dir By Michael Clayman)

Duration:

2m 11s

Description:

ACID! : Andrew "Loud Noize" Brower - Lead Guitarist/Lead Vocalist Matthew Daidone - Rhythm Guitarist Michael Clayman...

Yoshvim Perek 3: The Story Of Michael Clayman

Duration:

10m 31s

Description:

Watch the amazing story of this Jewish Lawyer as he found the Jewish Messiah.

Michael Clayman - Centre Midfield

Duration:

4m 13s

Biopharmaceutica... Manufacturing During Covid-19

Duration:

9m 3s

Description:

Appearing in this video (in order) are: Mike Clayman, M.D., CEO, Flexion Therapeutics Caroline Loew, Ph.D., CEO, Glympse...

Casting Glass With Daniel Clayman | Master Class Series, Volume Ix

Duration:

29m 56s

Description:

Daniel Clayman creates large-scale, cast-glass minimalist sculptures that evoke familiar objects and capture space and volume,...

Michael Clayman resumes & CV records

Resumes

Michael Clayman

Location:

United States

In the News

News

Flexion Meets Primary Endpoint In Phase 3 Trial Of Zilretta In Knee Osteoarthritis

Date:

Feb 17, 2016

Category:

Health

Source:

Pharmaceutical Business Review

Flexion Therapeutics president and CEO Michael Clayman said: "We believe that Zilretta has the potential to become an important new non-opioid treatment in a therapeutic area that hasn't seen meaningful innovation in many years.

Flexion's Pain Drug Comes Through In Phase Iii After A Prior Pivotal Failure

Date:

Feb 16, 2016

Category:

Health

Source:

FierceBiotech

"We believe that Zilretta has the potential to become an important new non-opioid treatment in a therapeutic area that hasn't seen meaningful innovation in many years," Flexion CEO Dr. Michael Clayman said in a statement.

Flexion Therapeutics Announces That Fda Has Removed Clinical Hold On Fx006

Date:

Dec 01, 2014

Category:

Health

Source:

CNNMoney

Michael Clayman, M.D., Flexion Therapeutics President and CEO, said, "We are pleased to have been able to rapidly provide data to the FDA that allowed the agency to remove the clinical hold. Now we can continue to advance FX006, which has the potential to make a real difference for the many individu

Possible Relatives

Cynthia L Clayman Deborah Clayman George L Clayman Gregory L Clayman Harry N Clayman Henry M Clayman Howard M Clayman Michael C Last Michael C Johnson Michael F Stamps

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.